Skip to main content

Table 3 Percent actuarial survival outcomes and control rates

From: Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer

Median Followup (range in months)

14 (1–36)

Local control at 1 year, at 14 months, (failed/controlled)

76%, 76% (3/13)

Regional control at 1 year, at 14 months, (failed/controlled)

79%, 68% (6/10)

Distant control at 1 year, at 14 months, (failed/controlled)

71%, 61.5% (5/11)

PFS at 1 year, at 14 months (progression/no progression)

42%, 32% (10/6)

Overall survival at 1 year, at 14 months (dead/alive)

78%, 78%, (4/12)